Voiding Disorders in Children After Sacrococcygeal Teratoma Resection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05182853

Acronym

TSC-URO

Enrollment

Registered

2022-01-10

Start date

2021-06-16

Completion date

2021-12-01

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurogenic Bladder, Sacrococcygeal Teratoma, Voiding Disorders

Keywords

Teratoma, sacrococcygeal region, urinary incontinence, neurogenic bladder, children

Brief summary

Sacrococcygeal teratomas are the most common neonatal tumors and require rapid and complete resection. Tumor nerve compression and pelvic surgical sequelae may lead to many and varied voiding disorders. Data concerning long-term vesico-sphincteric disorders are conflicting. Some studies find good functional results \[Cozzi et al., 2008; Draper et al., 2009\]. However other authors reveal neurologic bladder with detrusor sphincter dyssynergia \[Hambraeus et al., 2018\] and rise concerned about long-term renal function \[Khanna et al., 2019; Rehfuss et al., 2020\] even in the absence of clinical voiding disorders. Most of studies include young patients with other malformations such as anorectal malformations or dysraphisms which may impact the results. The main objective is to assess bladder dysfunction in children aged 6 to 18 years after isolated sacrococcygeal teratoma resection.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

6 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Children aged 6 to 18 * history of sacrococcygeal teratoma resection

Exclusion criteria

* Associated anorectal malformation * Associated neurological pathology

Design outcomes

Primary

Measure	Time frame	Description
Presence of voiding disorders	Day 1	Presence of voiding disorders will be assessed by the scale: Dysfonctional voiding scoring system

Secondary

Measure	Time frame	Description
Presence of defecation disorders	Day 1	The Presence of defecation disorders will be assessed by the scale: Bristol stool scale
Presence of secondary neurological bladder	Day 1	the Presence of secondary neurological bladder will be assessed by the uroflowmetry

Countries

France

Outcome results